NOT FOR DISTRIBUTION
Header cover image

Market Cap

NT$4.2b

Last Updated

2021/09/16 15:32 UTC

Data Sources

Company Financials +

Executive Summary

Bionime Corporation manufactures and sells medical instruments in Algeria, the United States, Switzerland, China, and internationally. More Details


Snowflake Analysis

Proven track record with mediocre balance sheet.

Share Price & News

How has Bionime's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4737 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: 4737's weekly volatility (2%) has been stable over the past year.


Market Performance


7 Day Return

-1.0%

4737

0.4%

TW Medical Equipment

0.2%

TW Market


1 Year Return

-4.2%

4737

7.0%

TW Medical Equipment

34.2%

TW Market

Return vs Industry: 4737 underperformed the TW Medical Equipment industry which returned 7% over the past year.

Return vs Market: 4737 underperformed the TW Market which returned 34.2% over the past year.


Shareholder returns

4737IndustryMarket
7 Day-1.0%0.4%0.2%
30 Day-2.1%3.0%4.2%
90 Day-2.8%-7.4%0.2%
1 Year-1.3%-4.2%10.0%7.0%38.1%34.2%
3 Year50.3%36.4%23.0%12.6%78.2%59.9%
5 Year85.7%46.8%8.9%-6.2%122.9%85.5%

Long-Term Price Volatility Vs. Market

How volatile is Bionime's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bionime undervalued compared to its fair value and its price relative to the market?

37.52x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 4737 (NT$69) is trading above our estimate of fair value (NT$20.84)

Significantly Below Fair Value: 4737 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 4737 is poor value based on its PE Ratio (37.5x) compared to the TW Medical Equipment industry average (22.8x).

PE vs Market: 4737 is poor value based on its PE Ratio (37.5x) compared to the TW market (16.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4737's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4737's PB Ratio (2.1x) is in line with the TW Medical Equipment industry average.


Future Growth

How is Bionime forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

14.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bionime has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Bionime performed over the past 5 years?

-16.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4737 has high quality earnings.

Growing Profit Margin: 4737's current net profit margins (6%) are higher than last year (1.9%).


Past Earnings Growth Analysis

Earnings Trend: 4737's earnings have declined by 16.5% per year over the past 5 years.

Accelerating Growth: 4737's earnings growth over the past year (191.2%) exceeds its 5-year average (-16.5% per year).

Earnings vs Industry: 4737 earnings growth over the past year (191.2%) exceeded the Medical Equipment industry 9.5%.


Return on Equity

High ROE: 4737's Return on Equity (5.6%) is considered low.


Financial Health

How is Bionime's financial position?


Financial Position Analysis

Short Term Liabilities: 4737's short term assets (NT$1.4B) exceed its short term liabilities (NT$1.2B).

Long Term Liabilities: 4737's short term assets (NT$1.4B) exceed its long term liabilities (NT$1.3B).


Debt to Equity History and Analysis

Debt Level: 4737's debt to equity ratio (97.3%) is considered high.

Reducing Debt: 4737's debt to equity ratio has increased from 64.5% to 97.3% over the past 5 years.

Debt Coverage: 4737's debt is not well covered by operating cash flow (10.6%).

Interest Coverage: 4737's interest payments on its debt are well covered by EBIT (3.8x coverage).


Balance Sheet


Dividend

What is Bionime current dividend yield, its reliability and sustainability?

2.99%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 4737's dividend (2.99%) is higher than the bottom 25% of dividend payers in the TW market (1.94%).

High Dividend: 4737's dividend (2.99%) is low compared to the top 25% of dividend payers in the TW market (5.26%).


Stability and Growth of Payments

Stable Dividend: 4737's dividend payments have been volatile in the past 10 years.

Growing Dividend: 4737's dividend payments have fallen over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (111.4%), 4737's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Roy Huang

no data

Tenure

Mr. Chun-Mu Huang also known as Roy, founded Bionime Corporation in 2002. Mr. Huang serves as Chairman and General Manager of Bionime Corporation and has been its Director since April 14, 2003. He Complete...


Leadership Team

Experienced Management: 4737's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: 4737's board of directors are seasoned and experienced ( 11.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bionime Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bionime Corporation
  • Ticker: 4737
  • Exchange: TWSE
  • Founded: 2003
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: NT$4.153b
  • Shares outstanding: 60.20m
  • Website: https://www.bionime.com

Location

  • Bionime Corporation
  • No. 100, Daqing Street
  • Sec. 2
  • Taichung
  • 40242
  • Taiwan

Listings


Biography

Bionime Corporation manufactures and sells medical instruments in Algeria, the United States, Switzerland, China, and internationally. It offers medical testing blood glucose management products for self-m...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/16 15:32
End of Day Share Price2021/09/16 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.